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ApoptosisPPP2R5E belongs to the phosphatase 2A regulatory subunit B family and acts as a tumor suppressor
in human cancer. However, the role of PPP2R5E in the tumorigenesis of gastric cancer is unclear.
Here, we declare that PPP2R5E is downregulated by miR-23a and induces cell growth inhibition
and apoptosis in gastric cancer cells. Furthermore, ASO-miR-23a suppresses tumor growth derived
from MGC803 cells in vivo. PPP2R5E is identiﬁed as a new target of miR-23a. Moreover, overexpres-
sion of PPP2R5E reversed the negative effects of miR-23a. We highlight the signiﬁcance of miR-23a
and PPP2R5E in the proliferation and apoptosis of gastric cancer cells.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer, which ranks as the second leading cause of can-
cer worldwide, has a poor prognosis and a high mortality rate
[1–3]. Previous reports have demonstrated that gastric cancer is
a disease involving multiple factors and steps [4–6]. Accumulated
evidence has shown that the pathogenesis of gastric cancer
involves the activity of oncogenes or tumor suppressors [7,8].
However, the molecular mechanisms underlying the development
and progression of gastric cancer remain unknown. Serine/threo-
nine-protein phosphatase 2A 56-kDa regulatory subunit epsilon
isoform (PPP2R5E) belongs to the phosphatase 2A (PP2A) regula-
tory subunit B family and acts as a tumor suppressor in human
cancers. Recent studies have reported that the presence of poly-
morphisms in PP2A subunit genes, including the PPP2R5E gene,
increase the risk for lung cancer [9]. However, the role of PPP2R5E
in the development of gastric cancer is unknown.
miRNAs are a group of evolutionarily conserved, small non-cod-
ing single-stranded RNAs that can regulate gene expression bybinding to speciﬁc regions of target mRNAs to induce mRNA degra-
dation or to suppress mRNA translation [10–12]. miRNAs partici-
pate in different physiological processes, depending on their
target gene [13,14]. Some miRNAs can function as oncogenes and
participate in tumorigenesis [15]. miR-19a/b has been shown to
facilitate the migration, invasion and metastasis of gastric cancer
cell in vitro and in vivo [16], and miR-23a and miR-27a were
shown to be highly expressed in gastric cancer cells and to contrib-
ute to their growth [17–19]. In contrast, other miRNAs have been
shown to function as tumor suppressor genes and to be expressed
at a low level in tumor tissues. The expression of the miR-200bc/
429 cluster, miR-497 and miR-181b, which negatively regulate
the expression of BCL2 and contribute to the apoptosis-mediated
multidrug resistance, is downregulated in gastric cancer cell lines
[20–22].
Recently, miR-23a was found to perform various biological
functions in different types of tumors; in gastric tumors, miR-23a
was found to target MT2A and to promote tumor growth [23].
The Fas signaling pathway has been shown to induce the epithe-
lial–mesenchymal transition (EMT) to promote the metastasis of
gastrointestinal cancer cells, but the involvement of miRNAs in this
mechanism is unknown. Zheng found that treatment with the Fas
ligand inhibited the expression of E-cadherin and promoted cell
invasion by upregulating the expression of miR-23a, whereas the
overexpression of an miR-23a inhibitor partially blocked this
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and is involved in antagonizing the lymphoid cell fate [25]. Yong
found that miR-23a appeared to be a potential blood biomarker
for the early detection of colorectal cancer [26]. miR-23a promoted
the metastasis of neuroblastoma cells through inhibiting the
expression of the CDH1 gene [27] and targeted glutaminase (GLS)
mRNA and inhibited the expression of GLS protein in human leuke-
mic cells [28]. The miR-23a/24/27a cluster promoted cellular pro-
liferation and suppressed apoptosis in liver cancer cells [29].
Compared with the level in normal bladder mucosa, the level of
expression of miR-23a was signiﬁcantly upregulated in bladder
cancers [30].
In the current study, we found that PPP2R5E promoted
apoptosis to suppress the growth of cells of gastric cancer cell
lines and its expression was downregulated in human gastric
cancer tissues. Furthermore, miR-23a was identiﬁed as a regula-
tor of PPP2R5E expression. The suppression of PPP2R5E expres-
sion through binding the 30 UTR of miR-23a promoted the
growth and suppressed the apoptosis of gastric cancer cells
and promoted the growth of tumors derived from MGC803 cells
in vitro and in vivo. Thus, a decrease in the level of PPP2R5E
expression and a concomitant increase in the level of miR-23a
expression in gastric cancer tissues appears to promote gastric
carcinogenesis.
2. Materials and methods
2.1. Human cancer tissue specimens and RNA isolation
Freshly frozen human gastric cancer tissue and matched non-
tumor gastric tissue specimens were obtained from the Tumor
Bank Facility of Tianjin Medical University Cancer Institute and
Hospital and from the National Foundation for Cancer Research.
The subtype of each tumor was veriﬁed by histological analysis.
The use of human materials conformed to the policies of our Insti-
tutional review board. The total RNA was extracted using the mir-
Vana miRNA Isolation Kit (Ambion, Austin, TX). Large RNAs (those
larger than 200 nt) and small RNAs (those smaller than 200 nt)
were separated and puriﬁed following the manufacturer’s
instructions.Table 1
The oligonucleotides used in this work.
Name Sequence (50–
pri-miR-23a forward 50-GCGAGATC
pri-miR-23a reverse 50-GATGAATT
ASO-miR-23a 50-GGAAATCC
ASO-NC 50-GTGGATAT
PPP2R5E-30 UTR-S 50-CGCGGATC
PPP2R5E-30 UTR-A 50-CGGGATTC
PPP2R5E-30 UTR-MS 50-GATACAAT
PPP2R5E-30 UTR-MA 50-GCTAAATT
PPP2R5E-qPCR-AS 50 GTAGCATT
PPP2R5E-qPCR-S: 50 TTGGAGTT
PPP2R5E-S-BamHI 50 GCGGATCC
PPP2R5E-AS-XhoI 50 CCCCTCGA
PPP2R5E-siR-Top 50-GATCCGCA
PPP2R5E-siR-Bot 50-AGCTTTTC
b-Actin-S 50-CGTGACAT
b-Actin-A 50-CTAGAAGC
miR-23a-RT 50-GTCGTATC
U6 RT 50-GTCGTATC
miR-23a forward 50-TGCGGATC
U6 forward 50-TGCGGGTG
Reverse 50-CCAGTGCA
GAPDH-S 50-GCGAATTC
GAPDH-AS 50-GCTACTCG2.2. Quantitative reverse transcription–PCR (qRT-PCR)
qRT-PCR was performed to detect the levels of miR-23a and
protein phosphatase 2 regulatory subunit B0 (PPP2R5E) mRNAs in
the tissue specimens. The small RNAs that were extracted from
the tissue were reverse transcribed into cDNA. The cDNA was used
to amplify mature miR-23a transcripts and the endogenous con-
trol, U6 snRNA, using PCR. To quantify PPP2R5E gene expression,
5 lg of RNA extracted from cells or tissue specimens was reverse
transcribed to cDNA using M-MLV reverse transcriptase. PCR
ampliﬁcation was performed using the SYBR Premix Ex Taq™ kit
(TaKaRa, Otsu, Shiga, Japan), and qRT-PCR was performed using
an iQ5 qRT-PCR detection system (Bio-Rad, Hercules, CA). The rel-
ative gene expression levels were calculated using the 2DDct
method [31]. All of the primers were purchased from AuGCT, Inc.
(Beijing, China), and the sequences of the primers are shown in
Table 1.
2.3. Immunohistochemistry
Immunohistochemistry was performed according to previously
described methods [32]. The sections were pretreated using micro-
wave irradiation, then were blocked and incubated with polyclonal
rabbit anti-human PPP2R5E antibodies (Saier Biotechnology). The
staining intensity was then assessed.
2.4. Plasmid construction
The pSilencer/shRNA-PPP2R5E (sh-PPP2R5E) vector was
obtained by annealing two single-stranded complementary
sequences that contained BamHI and HindIII restriction sites at
the ends. The fragment was then cloned into the pSilencer2.1/
neo vector (Ambion) between the BamHI and HindIII sites. A
1400-bp fragment was inserted into the pCD3/3ﬂag vector, which
contained BamHI and XhoI restriction sites. The pcDNA3 vector
was used to generate a PPP2R5E-overexpression plasmid. The
full-length human PPP2R5E cDNA sequence (GenBank TM,
NM_017423.2) was ampliﬁed by PCR using cDNA isolated from
fetal brain tissue as the template. The PPP2R5E gene was inserted
into the EcoRI and XbaI restriction sites. The construction of the30)
TGGCTCCTGCATATGAG-30
CCAGGCACAGGCTTCGG-30
CTGGCAATGTGAT-30
TGTTGCCATCA-30
CAAATTCCATTATCGGGAG-30
TCCAGAGGAGGATGTTACAC-30
TTTCATAAGAGTACAATCTTAAATTTAGC-30
TAAGATTGTACTCTTATGAAAATTGTATC-30
TGTAGAACCAC 30
GTTGCCTTAC 30
AAAGTAGGGATATG 30
GTTAGATGTTGTTGTCATT 30
GAAGAAGATGAACCTACTTC AAGAGAGTAGGTTCATCTTCTTCTGTTTTTT GGAAA-30
CAAAAAACAGAAGAAGAT GAACCTACTCTCTTGAAGTAGGTTCATCTTC TTCTGCG-30
TAAGGAGAAGCTG-30
ATTTGCGGTGGAC-30
CAGTGCAGGGTCCGAGGTGCACTGGATACGACGGAAATCC-30
CAGTGCAGGGTCCGAGGTGCACTGGATACGACAAAATATGG-30
ACATTGCCAGG-30
CTCGCTTCGGCAGC-30
GGGTCCGAGGT-30
CGTGTCCCCACTGCCAACGTGTC-30
AGTTACTCCTTGGAGGCCATGTGG-30
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published paper [33]. We also had a 20-O-methyl-modiﬁed
antisense oligonucleotide directed against miR-23a (ASO-miR-
23a) synthesized commercially (GenePharm, Shanghai, China).
The sequence of the ASO-miR-23a construct that was used in this
study is shown in Table 1. The enhanced green ﬂuorescent protein
(EGFP) expression vector (pcDNA3/EGFP) was constructed as pre-
viously described. The 30 UTR fragment of the PPP2R5E gene con-
taining the predicted miR-23a binding site was ampliﬁed by PCR
using the primers. The PCR products were cloned into the
pcDNA3/EGFP plasmid between the BamHI and EcoRI restriction
sites, and the resulting vector was named pcDNA3/EGFP-PPP2R5E
30 UTR. Moreover, a mutant fragment of the PPP2R5E 30 UTR, which
contained a mutated miR-23a binding site, was ampliﬁed by PCR
site-directed mutagenesis and cloned into the pcDNA3/EGFP plas-
mid between the BamHI and EcoRI restriction sites (pcDNA3/EGFP-
PPP2R5E 30 UTR-mut). All of the inserted DNAs mentioned above
were veriﬁed by DNA sequencing. The primers are shown in
Table 1.
2.5. Western blotting analysis
At 72 h after transfection, the cells were collected and lysed
using RIPA lysis buffer (0.15 M NaCl, 0.05 M Tris HCl, pH 7.2, 1%
Triton X-100 and 0.1% SDS). The protein concentration was deter-
mined using the BCA reagent purchased from Promega. Approxi-
mately 25 lg of each protein sample was subjected to SDS–PAGE
and then transferred to a nitrocellulose membrane. The mem-
branes were blocked using 5% blotto for 2 h at room temperature,
followed by an overnight incubation at 4 C with anti-PPP2R5E
(1:200) and anti-tubulin (1:1000) antibodies, and then were incu-
bated with HRP-conjugated secondary antibody (1:1000). The
bands were detected using an enhanced chemiluminescence
reagent and the membranes were exposed to autoradiographicFig. 1. The level of PPP2R5E expression in gastric cancer tissues. (A) The relative level of
actin was included as an endogenous control (n = 20, P < 0.05). (B) The level of expressio
using immunohistochemistry (n = 20, P < 0.05).ﬁlm, and then the band intensities were quantitated using Analysis
Software. The antibodies were obtained from Saier Biotechnology.
2.6. Cell culture and transfection
The MGC803 and BGC823 human gastric cancer cell lines were
purchased from the Cell Bank of the Type Culture Collection of the
Chinese Academy of Sciences, Shanghai Institute of Cell Biology,
Chinese Academy of Sciences. The cells were grown in RPMI1640
medium (GIBCO BRL, Grand Island, NY, USA) containing with 10%
fetal bovine serum (FBS), 100 IU/mL of penicillin and 0.1 mg/mL
of streptomycin. These two cell lines express high levels of miR-
23a, which remained stable during culturing, passaging and trans-
fection in our laboratory; therefore, we chose these two cell lines
for the functional studies.
One day before transfection, the cells were plated in a 48-well
plate at approximately 2  104 cells/well. The transfections were
performed using Lipofectamine 2000 reagent according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). The oligo-
nucleotides and plasmids were used at a ﬁnal concentration of
100 nM and 5 ng/lL, respectively. To determine the transfection
efﬁciency, we transfected either pcDNA3-EGFP or the negative con-
trol, pcDNA3, into the two cell lines and assessed the level of EGFP
expression 48 h after transfection using ﬂuorescence microscopy.
As expected, the efﬁciency of transfection was approximately 60–
70%.
2.7. MTT and colony-formation assays
The cells were seeded in a 96-well plate at 4  103 per well and
were transfected with 100 nM ASO-miR-23a or with 5 ng/lL of
each plasmid, as described above. At 48 and 72 h post-transfection,
the cells were incubated with 10 lL of MTT for 4 h and then were
dissolved in 100 lL of DMSO. After shaking for 10 min, the absor-PPP2R5E mRNA in 20 pairs of gastric cancer tissues was evaluated using qRT-PCR. b-
n of PPP2R5E in gastric cancer tissues and in matched normal tissues was assessed
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plate Spectrophotometer (Bio-tek Instruments).
After transfection, the cells were plated in 12-well plates at
300 BGC823 cells or 200 MGC803 cells per well for theFig. 2. Knocked-down expression or overexpression of PPP2R5E altered the
phenotypes of gastric cancer cells. (A) Cells of the MGC803 cell line were
transfected with pSilencer/sh-PPP2R5E, pcDNA3/3ﬂag-PPP2R5E or the appropriate
control vectors, and qRT-PCR was performed to detect the level of PPP2R5E
expression (n = 3, ⁄P < 0.05). (B) The PPP2R5E protein expression level in transfected
MGC803 cells was evaluated using western blotting analysis. The Arabic numerals
above the western blot image indicate the ratio of the densitometric values of
PPP2R5E and GAPDH compared with those of the control. (C) Cells of the MGC803
and BGC823 cell lines were transfected with pSilencer/sh-PPP2R5E, and the growth
and viability of the two cell lines were evaluated using the MTT assay (n = 3,
⁄⁄P < 0.01, ⁄⁄⁄P < 0.001). (D) Cell clonogenicity was evaluated using a colony-
formation assay. MGC803 cells were grown for 10 days, and BGC823 cells were
grown for 14 days. The images demonstrate the stained colonies (n = 3,⁄P < 0.05,
⁄⁄P < 0.01). (E) Paclitaxel (0.05 ppc) was added to the transfected cells to induce
apoptosis. A TUNEL assay was performed to detect apoptotic cells. The induced-
apoptosis indices are shown (n = 3, ⁄P < 0.05).colony-formation assay. During colony growth, the culture med-
ium was replaced every 3–5 days. The number of MGC803 and
BGC823 colonies was counted on the 10th day and 14th day,
respectively, after crystal-violet staining.
2.8. TUNEL assay
The terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) assay was performed using the In-Situ
Cell Death Detection Kit (Roche Diagnostics Corporation, India-
napolis, IN, USA). At 24 h after transfection, the cells were
seeded at 5  103 cells per well in 14-well plates. Then, the cells
were treated with 0.05 ppc paclitaxel for 1 h and ﬁxed using 4%
paraformaldehyde. Next, the cells were incubated in 0.1% Tri-
tonX-100 for 2 min on ice. After washing the cells, 4 lL of the
TUNEL reaction mixture was added to each well, and cells were
incubated for 1 h at 37 C the dark. Finally, DAPI (4,6-diamidino-
2-phenylindole, Dojindo Molecular Technologies, Inc., Japan) was
used to stain the nuclei. Fluorescence images were obtained at
an excitation wavelength of 488 nm for FITC-labeled nanoparti-
cles using NIS Elements F 2.20 imaging software (Nikon, Tokyo,
Japan).
2.9. Fluorescent reporter assay
MGC803 cells were transfected in 48-well plates with the
PPP2R5E EGFP reporter vector and with the wild-type or a mutated
30 UTR vector and were also co-transfected with miR-23a ASO or
pcDNA3/pri-23a. The RFP expression vector pDsRed2-N1 was
transfected at 0.05 lg per well (Clontech, Mountain View, CA,
USA). At 48 h after transfection, the cells were lysed using RIPA
buffer. The ﬂuorescence intensities of EGFP and red ﬂuorescent
protein were measured using a F-4500 ﬂuorescence spectropho-
tometer (Hitachi, Tokyo, Japan).
2.10. Murine xenograft model
Six-week-old female nude mice were purchased from the ani-
mal facilities of the Chinese Academy of Medical Sciences and were
housed in the animal facilities of Tianjin Medical University as
approved by the Institutional Animal Care and Use Committee.
MGC803 cells (4  106 cells/0.15 mL/mouse) were subcutaneously
injected into the ﬂanks of the nude mice. After 3 weeks, the mouse
were sacriﬁced, the tumors were harvested and measured, then
they were stored at 80 C for subsequent analysis.
2.11. Bioinformatic methods and statistical analysis
Bioinformatic methods were used to predict the miRNA targets
of miR-23a. we chose two commonly utilized algorithms, Target-
Scan Release 4.0 (http://www.targetscan.org) and PicTar (http://
pictar.bio.nyu.edu/cgi-bin/PicTar_vertebrate.cgi). PPP2R5E was
predicted as a candidate target gene of miR-23a.
Each experiment was performed in triplicate. The differences
between multiple groups were analyzed using an ANOVA,
and the signiﬁcance of the differences between independent
groups were evaluated using the paired Student’s t test, with P
set at <0.05.
3. Results
3.1. PPP2R5E expression is suppressed in gastric cancer cells
We ﬁrst performed qRT-PCR to examine the differential expres-
sion of PPP2R5E in 20 pairs of gastric cancer tissues and the adja-
Fig. 3. The effects of overexpression or knocking down the expression of miR-23a on MGC803 and BGC823 cells. (A) qRT-PCR was used to examine miR-23a expression in 20
pairs of gastric cancer tissues and their corresponding adjacent normal tissues. U6 RNA was included as an endogenous housekeeping gene, and the relative level of miR-23a
expression is shown (n =20, P < 0.05). (B) The Spearman correlation test was performed to analyze the inverse relationship between PPP2R5E and miR-23a expression in
gastric tissues (R2 = 0.9877). (C) miR-23a levels in MGC803 cells transfected with pcDNA3, pri-miR-23a, ASO-NC or ASO-miR-23a. U6 RNA was included as an endogenous
housekeeping gene (n = 3, ⁄⁄⁄P < 0.001). (D) The MTT assay was used to analyze the cell viability of MGC803 and BGC823 cells transfected with pcDNA3, pri-miR-23a, ASO-NC
or ASO-miR-23a 72 h after transfection (n = 3, ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001). (E) The colony-formation rate of MGC803 and BGC823 cells transfected with pcDNA3, pri-
miR-23a, ASO-NC or ASO-miR-23a. Representative images of stained colonies are shown (n = 3,⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001). (F) A TUNEL assay was used to evaluate
apoptosis among MGC803 and BGC823 cells transfected with pcDNA3, pri-miR-23a, ASO-NC or ASO-miR-23a and exposed to Paclitaxel (0.05 ppc). The induced-apoptosis
indices are shown (n = 3, ⁄P < 0.05).
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Fig. 4. ASO-miR-23a suppressed the growth of tumors derived from MGC803 cells
in nude mice. (A) The cancer cells were injected subcutaneously into two groups of
nude mice, and nodules were obtained from the 14 mice that were injected with
MGC803 cells transfected with ASO-miR-23a or ASO-NC (n = 7, ⁄P < 0.05). (B) The
cancer cells were injected subcutaneously into two groups of nude mice, and the
size of the tumors was monitored at different time points. The mean size of the
tumors per animal was plotted (n = 7, ⁄P < 0.05). (C) The average weight of the
tumor nodules derived from MGC803 cells that were transfected with ASO-NC or
ASO-miR-23a in SCID mice (n = 7, ⁄P < 0.05). (D) qRT-PCR and western blotting assay
were performed to evaluate the levels of miR-23a and PPP2R5E expression in the
tumor nodules. (E) The expression of PPP2R5E in the tumor nodules of the ASO-NC
and ASO-miR-23a groups was detected using immunohistochemistry (n = 7,
P < 0.05).
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showed that the expression of PPP2R5E mRNA was downregulated
in the 20 gastric cancer tissue specimens. To conﬁrm the reduced
levels of PPP2R5E expression in these tissues, we utilized immuno-
histochemical staining to detect the PPP2R5E protein levels. Com-
pared with those of the normal gastric tissues, the levels of
PPP2R5E protein expression were markedly decreased in the gas-
tric cancer specimens (Fig. 1B). These observations led us to expect
that the level of expression of PPP2R5E was repressed in gastric
cancer cells.
3.2. PPP2R5E suppressed the growth of and induced apoptosis in
gastric cancer cells
Previous studies have demonstrated that PPP2R5E played an
important role in suppressing tumor-cell proliferation and dis-
played tumor-suppressive properties in breast cancer [34]. To
determine its role in gastric cancer cells, we ﬁrst constructed a pSi-
lencer/sh-PPP2R5E plasmid to block the endogenous expression of
PPP2R5E, and a pCD3/3ﬂag-PPP2R5E vector that lacked the its 30
UTR. The expression of PPP2R5E in transfected MGC803 cells was
determined using qRT-PCR and western blotting analysis. As
shown in Fig. 2A and B, pSilencer/sh-PPP2R5E effectively sup-
pressed and pCD3/3ﬂag-PPP2R5E effectively increased the levels
of PPP2R5E mRNA and protein expression.
To evaluate the effect of PPP2R5E on cell viability, we per-
formed an MTT assay. Compared to that of the control groups,
knocking down PPP2R5E expression increased, whereas overex-
pression of PPP2R5E decreased, the viability of MGC803 and
BGC823 cells (Fig. 2C). After enhancing or blocking the expression
of PPP2R5E, the long-term and independent cellular growth ability
of these cells was evaluated using a colony-formation assay. Con-
sistent with the results of MTT assay, the inhibition of PPP2R5E
expression led to increased colony-formation ability, whereas the
overexpression of PPP2R5E led to a reduction of that ability in
MGC803 and BGC823 cells (Fig. 2D). Next, the TUNEL assay was
used to evaluate apoptosis in the gastric cancer cell lines. Knocking
down PPP2R5E expression decreased the relative apoptosis index
to 67% and 60% in MGC803 and BGC823 cells, respectively
(Fig. 2E). The overexpression of PPP2R5E increased the relative
apoptosis index by approximately 2.57-fold and 2.39-fold in
MGC803 and BGC823 cells, respectively (Fig. 2E), compared with
those of the negative control groups. Representative images show-
ing the apoptotic cells are shown in Fig. S1.
Together, these observations indicated that PPP2R5E repressed
cell viability and growth and promoted apoptosis in cells of the
gastric cancer cell lines, which provided evidence and support for
its tumor-suppressive role in gastric cancer.
3.3. miR-23a functions as an oncogene in gastric cancer cells
To explore the mechanism for the downregulation of PPP2R5E
expression in gastric cancer cells, bioinformatic analysis was uti-
lized to predict miRNAs that might serve as post-transcriptional
regulators of PPP2R5E. We found many miRNAs that could poten-
tially bind to the PPP2R5E 30 UTR, including miR-23a, miR-19, miR-
181 and others. Moreover, our previous study had revealed that
miR-23a expression was clearly upregulated in gastric cancer cells
[33]. Therefore, miR-23a was chosen for further investigation in
this study.
qRT-PCR was applied to detect the level of miR-23a expression
in another 10 pairs of gastric cancer tissue and matched normal
gastric tissue specimens to conﬁrm the upregulation of miR-23a
expression in gastric cancer tissue (Fig. 3A). We utilized the Spear-
man correlation to analyze the relationship between the expres-
sion PPP2R5E and miR-23a in the gastric cancer tissues. Asshown in Fig. 3B, the levels of miR-23a and PPP2R5E expression
had a strong inverse relationship (R2 = 0.9877). Human gastric can-
cer cells were transfected with the pri-miR-23a vector, ASO-miR-
23a and their respective controls, and the efﬁciency of the effect
of pri-miR-23a or ASO-miR-23a in BGC823 cells was validated
using qRT-PCR. We conﬁrmed that pri-miR-23a increased the level
of miR-23a expression and that ASO-miR-23a effectively decreased
it (Fig. 3C). The results of the MTT assay showed that cell viability
increased approximately 1.31-fold in MGC803 cells and 1.41-fold
in BGC823 cells when miR-23a was overexpressed. Conversely,
ASO-miR-23a reduced the viability of MGC803 cells to 72% and
that of BGC823 cells to 74% (Fig. 3D). The results of the colony-for-
mation assay revealed a marked reduction in the colony-formation
rate of MGC803 and BGC823 cells that were treated with ASO-miR-
23a relative to that of the corresponding negative controls.
Fig. 5. PPP2R5E is a direct target of miR-23a. (A) As predicted by the Target Scan and PicTar algorithms, the PPP2R5E 30 UTR has a miR-23a-binding site. The sequences of the
mutated PPP2R5E 30 UTR, in which several nucleotides within the miR-23a binding site were mutated, is shown. (B) The direct interaction between miR-23a and the PPP2R5E
30 UTR was conﬁrmed using an EGFP-reporter assay. MGC803 cells were transfected with the EGFP-PPP2R5E 30 UTR reporter gene and with pcDNA3, pri-miR-23a, ASO-NC or
ASO-miR-23a (n = 3, ⁄P < 0.05). (C) The ﬂuorescence intensity of MGC803 cells that were transfected with the EGFP vector, the PPP2R5E 30 UTR reporter or the mutant EGFP-30
UTR reporter in addition to pcDNA3, pcDNA3/pri-miR-23a, ASO-NC or ASO-miR-23a. (D) The level of expression of PPP2R5E mRNA in MGC803 and BGC823 cells that were
transfected with pcDNA3, pcDNA3/pri-miR-23a, ASO-NC or ASO-2miR-3a was determined using qRT-PCR (n = 3, ⁄P < 0.05).
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the colony-formation ability of these two human gastric cancer cell
lines (Fig. 3D and E). To assess whether miR-23a had an effect on
cellular apoptosis, we performed the TUNEL assay in parallel. Com-
pared with those of the negative control groups, the apoptosis
index was approximately 62% or 54% lower in the pri-miR-23a
groups and 1.69 or 1.78-fold higher in the ASO-miR-23a groups
of MGC803 or BGC823 cells, respectively (Fig. 3E and F). Moreover,
overexpression of miR-23a resulted in a signiﬁcantly reduced rate
of apoptosis of MGC803 and BGC823 cells, and the opposite result
was obtained in cells that were transfected with ASO-miR-23a
(Fig. S2). Collectively, these observations strongly suggested that
miR-23a is apparently capable of suppressing apoptosis and pro-
moting the growth, viability and colony-formation ability of
MGC803 and BGC823 cells.
To examine the effect of miR-23a on the growth of tumors
in vivo, we transfected MGC803 cells with ASO-miR-23a or ASO-
NC and injected the transfected cells into the ﬂanks of 7 nude mice.
The tumor nodules recovered after sacriﬁcing the mice are shown
in Fig. 4A. The average size (Fig. 4B) and weight (Fig. 4C) of the
tumors in the ASO-miR-23a group were less than those of theASO-NC group. We also examined the level of miR-23a and
PPP2R5E expression in the tumor nodules. The results showed that
the miR-23a level of the tumor nodules from the ASO-miR-23a
group was decreased to 27% but their levels of PPP2R5E mRNA
and protein were increased 3.4-fold and 1.7-fold, respectively,
compared with those of the control group (Fig. 4D). Moreover,
immunohistochemical staining showed a high level of PPP2R5E
in the tumor nodules from the ASO-miR-23a group (Fig. 4E). These
data indicated that knocking down miR-23a expression suppressed
tumor growth in vivo. Taken together, these results indicated that
miR-23a plays a role as an oncogene in gastric cancer.
3.4. PPP2R5E is a target of miR-23a
PPP2R5E is a tumor suppressor and may be a target of miR-23a,
which is consistent with miR-23a being regarded as an oncogenic
gene. To determine whether miR-23a could regulate the expres-
sion of PPP2R5E, we used various algorithms to predict comple-
mentary miR-23a-binding sites in the 30 UTR of PPP2R5E mRNA
and determined whether these binding sites were conserved
among several species (Fig. 5A). To evaluate whether miR-23a
X. Liu et al. / FEBS Letters 588 (2014) 3160–3169 3167could directly bind to a target site in the PPP2R5E 30 UTR, we con-
structed an enhanced green ﬂuorescent protein reporter vector
(EGFP-PPP2R5E 30 UTR) carrying the PPP2R5E 30 UTR or a mutant
PPP2R5E 30 UTR (EGFP-PPP2R5E 30 UTR or EGFP-PPP2R5E 30 UTR
mutant) in which the predicted target regions were cloned down-
stream of the EGFP stop codon. Additionally, we constructedFig. 6. Restoration of PPP2R5E expression rescued the miR-23a-induced cellular
phenotype. MGC803 and BGC823 cells were co-transfected with pri-miR23a and
pcDNA3/3ﬂag-PPP2R5E or pcDNA3; the pcDNA3 group served as the control. (A)
Western blotting analysis was used to evaluate the expression of PPP2R5E protein.
The Arabic numerals above the western blot image indicate the densitometric ratios
of PPP2R5E and GAPDH compared with that of the control. (B) Cell viability was
determined using an MTT assay 72 h after transfection (n = 3, ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001). (C) Cell clonogenicity was evaluated using a colony-formation assay.
The images under the graph show the stained colonies (n = 3,⁄P < 0.05, ⁄⁄⁄P < 0.001).
(D) A TUNEL assay was performed to evaluate apoptosis in the transfected cells.
Paclitaxel (0.05ppc) was added to the transfected cells to induce apoptosis. The
induced-apoptosis indices are shown (n = 3, ⁄P < 0.05).another EGFP reporter vector (Fig. 5A). pcDNA3 or pri-miR-23a
and ASO-NC or ASO-miR-23a were co-transfected into MGC803
cells with the reporter vector (EGFP-PPP2R5E 30 UTR or EGFP-
PPP2R5E 30 UTR mutant). Compared with the negative control,
pri-miR-23a reduced and ASO-miR-23a enhanced the expression
of EGFP (Fig. 5B). In contrast, no changes in the intensity of ﬂuores-
cence driven by the mutant reporter plasmid were observed upon
the overexpression or knocked down expression of miR-23a
(Fig. 5C). These observations suggested that miR-23a binds to the
30 UTR of PPP2R5E directly.
Next, we examined the level of endogenous PPP2R5E expression
when the level of miR-23a expression was altered. qRT-PCR was
performed to assess the expression of PPP2R5E mRNA. When
miR-23a was overexpressed, the level of PPP2R5E mRNA was
reduced compared with that of the negative group (Fig. 5D). Con-
versely, compared with that of the ASO-NC groups, the level of
PPP2R5E expression in ASO-miR-23a-transfected MGC803 and
BGC823 cells was increased (Fig. 5D). Collectively, these results
suggested that miR-23a repressed the endogenous expression of
PPP2R5E by binding its 30 UTR directly.
3.5. miR-23a promoted gastric cancer cell growth by downregulating
the expression of PPP2R5E
To conﬁrm whether the effects of miR-23a expression on cell
proliferation and apoptosis were mediated by PPP2R5E, we overex-
pressed miR-23a and PPP2R5E in MGC803 and BGC823 cells. Com-
pared with the effect of transfection with the control vector,
transfection with pcDNA3/PPP2R5E reversed the negative effects
of miR-23a on the expression of PPP2R5E (Fig. 6A). Overexpression
of PPP2R5E reversed the increase in cell viability caused by miR-
23a (Fig. 6B), and similar results were observed using the colony-
formation assay (Fig. 6C). Overexpression of PPP2R5E also neutral-
ized the inhibition of cellular apoptosis that was induced by miR-
23a expression, as shown using the TUNEL assay (Fig. S3). Overex-
pression of PPP2R5E reversed the repressive effects of miR-23a on
apoptosis from 45% to 89% in MGC803 cells and from 50% to 90% in
BGC823 cells (Fig. 6D) compared with the rates in the control cells.
It was noted above that PPP2R5E exerts a tumor-suppressor
activity, is directly inhibited by miR-23a and is involved in the
miR-23a-mediated malignant phenotype of gastric cancer cells.
To summarize, miR-23a plays a growth-stimulating role in gastric
cancer cells through at least partially downregulating the expres-
sion of PPP2R5E.4. Discussion
Protein phosphatase 2A (PP2A) is a serine/threonine-speciﬁc
phosphatase that plays central roles in cellular development,
growth and transformation [35]. The role of PP2A as a tumor sup-
pressor that controls tumor progression is thought to be governed
by a small subset of speciﬁc B subunits that direct PP2A to dephos-
phorylate certain substrates [36]. The ﬁndings of this study
support the previously hypothesized role of PP2A as a tumor sup-
pressor gene in breast cancer [34]. In addition, PP2A is involved in
cellular transformation as an important tumor suppressor. A large
body of evidence suggests that PP2A is a tumor suppressor and
plays critical roles in regulating apoptosis [37,38]. Cristobal’s group
has reported that the inhibition of PP2A is a common event in the
genesis of AML and that restoration of the activity of PP2A induces
cell-growth arrest and caspase-dependent apoptosis [39].
Herein, we demonstrated that the overexpression of PPP2R5E, a
regulatory subunit of PP2A, promoted paclitaxel-induced apoptosis
and that knocking down the expression of PPP2R5E inhibited apop-
tosis in gastric cancer cells. PPP2R5E, which impairs cell prolifera-
3168 X. Liu et al. / FEBS Letters 588 (2014) 3160–3169tion and induces caspase-dependent apoptosis, was consistently
found to affect the activation status of AKT and to reduce the col-
ony-forming ability of leukemic cells [40]. PPP2R5E is also involved
in multiple signaling pathways and plays a critical role during early
development [41–43]. Moreover, PPP2R5E is an essential regulator
of apoptosis and acts as a negative regulator of MAP4K3 by medi-
ating its ability to signal to mTORC1 [44]. PPP2R5E suppresses p53-
independent apoptosis during neural development but triggers
p53-dependent apoptosis [45]. Recently, Mavrakis et al. found that
the oncogenic properties of miR-19b in acute lymphoblastic leuke-
mia were due, at least in part, to its inhibitory effect on PP2A via
downregulating the expression of PPP2R5E [38]. Therefore, we
hypothesized that, as an important regulatory subunit of PP2A,
PPP2R5E acted as a tumor suppressor and played important roles
in regulating apoptosis in gastric cancer. Thus, we investigated
whether miR-23a regulated the expression of PPP2R5E in the
post-transcriptional stage in gastric cancer cells. First, we found
that the expression of PPP2R5E was downregulated in gastric can-
cer cells, and that knocking down the expression of PPP2R5E
induced cell-growth inhibition and apoptosis in gastric cancer
cells. In our previous study, we used oligonucleotide microarrays
to determine that miR-23a expression was upregulated in gastric
cancer samples [17]. Thus, we speculated that the downregulation
of PPP2R5E expression might be mediated by miR-23a, which
might contribute to carcinogenesis. To address this hypothesis,
we ﬁrst used bioinformatics to predict that PPP2R5E is a target
gene of miR-23a and then demonstrated an inverse relationship
between the upregulation of miR-23a expression and the downreg-
ulation of PPP2R5E expression in gastric cancer cells. Furthermore,
we determined that the expression of a 30 PPP2R5E-UTR-based
reporter construct was negatively regulated by miR-23a. Over-
expressing PPP2R5E was sufﬁcient to counteract the miR-23a-
mediated promotion of cellular proliferation and repression of cel-
lular apoptosis. Finally, the results of an animal study suggested
that miR-23a promoted the growth of MGC803 tumor cells
in vivo. Thus, we have provided evidence that the partial downreg-
ulation of PPP2R5E expression by miR-23a may contribute to gas-
tric tumorigenesis.
In summary, the expression of PPP2R5E was suppressed in gas-
tric cancer cells, which promoted the malignant behavior of these
cells. The upregulation of miR-23a expression resulted in the
downregulation of PPP2R5E expression at the post-transcriptional
level, and the anti-proliferative and pro-apoptotic activities of
PPP2R5E were negatively regulated by miR-23a, which might pro-
vide a partial explanation for the downregulation of PPP2R5E
expression in gastric cancer cells.
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